Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$50M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$50M
- +24.6% YoY · +27.0% QoQ
- EPS (diluted)
- −$0.45
- +36.6% YoY · +27.4% QoQ
Source: XBRL data from the ROCKET PHARMACEUTICALS, INC. (RCKT) Q3 2025 10-Q on SEC EDGAR. USD.
ROCKET PHARMACEUTICALS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- RP-A501 Phase 2 dosing resumed at 3.8×10¹³ GC/kg after clinical hold
- Six Danon disease patients treated in Phase 2; next three patients under sequential four-week monitoring
- Workforce reduction approximately 30%; 12-month operating expenses expected down nearly 25%
Risk Factors
- Securities litigation triggered by two class actions over RP-A501 statements and an October 22, 2025 derivative complaint
- Internal-controls and insider-trading allegations added to derivative litigation against officers and directors
- Strategic reorganization launched July 23, 2025, including 30% workforce reduction and nearly 25% expected operating-expense savings
- Restructuring execution risk from attrition, operational disruption, and difficulty retaining qualified personnel
- Litigation exposure could materially reduce cash resources through defense costs and adverse judgments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ROCKET PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.